- Home
- TCRX vs BDTX Comparison
TCRX vs BDTX Comparison
Compare TCRX & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- BDTX
- Stock Information
- Founded
- TCRX 2018
- BDTX 2014
- Country
- TCRX United States
- BDTX United States
- Employees
- TCRX N/A
- BDTX N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TCRX Health Care
- BDTX Health Care
- Exchange
- TCRX Nasdaq
- BDTX Nasdaq
- Market Cap
- TCRX 170.1M
- BDTX 144.9M
- IPO Year
- TCRX 2021
- BDTX 2020
- Fundamental
- Price
- TCRX $2.40
- BDTX $2.20
- Analyst Decision
- TCRX Strong Buy
- BDTX Strong Buy
- Analyst Count
- TCRX 5
- BDTX 4
- Target Price
- TCRX $11.40
- BDTX $15.50
- AVG Volume (30 Days)
- TCRX 544.4K
- BDTX 1.2M
- Earning Date
- TCRX 03-05-2025
- BDTX 03-11-2025
- Dividend Yield
- TCRX N/A
- BDTX N/A
- EPS Growth
- TCRX N/A
- BDTX N/A
- EPS
- TCRX N/A
- BDTX N/A
- Revenue
- TCRX $9,362,000.00
- BDTX N/A
- Revenue This Year
- TCRX N/A
- BDTX N/A
- Revenue Next Year
- TCRX $5.14
- BDTX N/A
- P/E Ratio
- TCRX N/A
- BDTX N/A
- Revenue Growth
- TCRX N/A
- BDTX N/A
- 52 Week Low
- TCRX $2.38
- BDTX $1.91
- 52 Week High
- TCRX $9.69
- BDTX $7.66
- Technical
- Relative Strength Index (RSI)
- TCRX 25.27
- BDTX 46.41
- Support Level
- TCRX $2.60
- BDTX $2.02
- Resistance Level
- TCRX $2.85
- BDTX $2.33
- Average True Range (ATR)
- TCRX 0.17
- BDTX 0.18
- MACD
- TCRX 0.00
- BDTX 0.03
- Stochastic Oscillator
- TCRX 2.41
- BDTX 38.16
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.